Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
- PMID: 12400004
- DOI: 10.1038/sj.onc.1206004
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
Abstract
Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that activate these survival genes in specific sites of metastasis. Estrogen receptor-negative breast cancer cell line MDA-MB435 and two metastatic sublines derived from lung (435L) and brain (435B) were analysed for the expression of members of the Bcl-2 family of apoptosis regulators. The levels of Bcl-2 were higher in the metastatic sublines than in parental cells, which correlated with the activation of Stat3, but not with the expression and/or activation of known bcl-2 transcription factors (CREB and WT1). In the brain subline, both expression of Bcl-2 and Stat3 activation were induced by epidermal growth factor and abrogated after treatment with kinase inhibitors specific for epidermal growth factor receptor or Jak2. Furthermore, transfection of 435B with a dominant-negative Stat3 markedly reduced the expression of Bcl-2 protein, whereas transient expression of a constitutively active Stat3 increased Bcl-2 in parental 435 cells. In addition, blockade of Stat3 activation by treatment with epidermal growth factor receptor and Jak2 kinase inhibitors or transfection with a dominant negative Stat3, sensitizes 435B cells to chemotherapy-induced apoptosis. Our data suggest that an increased activation of the Stat3-Bcl-2 pathway in estrogen receptor-negative metastatic breast cancer cell lines confer a survival advantage to these cells and contribute to their chemoresistance.
Similar articles
-
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.Oncogene. 2003 Jul 3;22(27):4150-65. doi: 10.1038/sj.onc.1206479. Oncogene. 2003. PMID: 12833138
-
Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.Cancer Lett. 2007 Dec 18;258(2):181-8. doi: 10.1016/j.canlet.2007.08.019. Epub 2007 Oct 24. Cancer Lett. 2007. PMID: 17920763
-
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells.Oncogene. 2001 Nov 29;20(55):7925-34. doi: 10.1038/sj.onc.1204990. Oncogene. 2001. PMID: 11753675
-
Regulation of Bcl-xL: a little bit of this and a little bit of STAT.Curr Opin Oncol. 2000 Nov;12(6):543-9. doi: 10.1097/00001622-200011000-00006. Curr Opin Oncol. 2000. PMID: 11085453 Review.
-
Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis.Cancer Cell. 2004 Jan;5(1):3-4. doi: 10.1016/s1535-6108(03)00338-6. Cancer Cell. 2004. PMID: 14749119 Review.
Cited by
-
Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin.Bioengineered. 2021 Dec;12(1):1874-1889. doi: 10.1080/21655979.2021.1924544. Bioengineered. 2021. PMID: 34076564 Free PMC article.
-
Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.Cell Commun Signal. 2021 May 6;19(1):50. doi: 10.1186/s12964-021-00705-2. Cell Commun Signal. 2021. PMID: 33957948 Free PMC article. Review.
-
Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo.Exp Ther Med. 2010 Nov;1(6):947-953. doi: 10.3892/etm.2010.156. Epub 2010 Sep 29. Exp Ther Med. 2010. PMID: 22993624 Free PMC article.
-
Case report: 16-yr life history and genomic evolution of an ER+ HER2- breast cancer.Cold Spring Harb Mol Case Stud. 2020 Dec 17;6(6):a005629. doi: 10.1101/mcs.a005629. Print 2020 Dec. Cold Spring Harb Mol Case Stud. 2020. PMID: 33008833 Free PMC article.
-
TTI-101 targets STAT3/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and computational analysis.Cancer Cell Int. 2024 Aug 12;24(1):286. doi: 10.1186/s12935-024-03463-6. Cancer Cell Int. 2024. PMID: 39135042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous